A Phase 1b, Open Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Crizotinib (Pf-02341066) In Patients With Advanced Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Jun 2019
Price : $35 *
At a glance
- Drugs Axitinib (Primary) ; Crizotinib (Primary)
- Indications Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 20 Jun 2019 Planned End Date changed from 31 Jul 2018 to 30 Aug 2019.
- 06 Jun 2017 Results (n=37; as of Aug 5, 2016), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 Planned End Date changed from 1 Oct 2017 to 1 Jul 2018.